West Pharma (NYSE: WST) reported Q2 EPS of $1.52, $0.22 worse than the analyst estimate of $1.74. Revenue for the quarter came in at $702.1 million versus the consensus estimate of $729.36 million.

GUIDANCE:

West Pharma sees FY2024 EPS of $6.35-$6.65, versus the consensus of $7.74. West Pharma sees FY2024 revenue of $2.87-2.9 million, versus the consensus of $3.01 million.

For earnings history and earnings-related data on West Pharma (WST) click here.